Reshaping the way you approach reproductive health

Helping you advance breakthroughs and possibly enable future early intervention

Reproductive & Genetic Health Products & Services

Preconception and Fertility Products

Preimplantation Genetic Screening

VeriSeq PGS Kit

Takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.

BlueFuse Multi Software

Provides in vitro fertilization (IVF) data analysis in a single framework.

24sure Microarrays

Provides a comprehensive and accurate assessment of all 24 chromosomes from an embryo biopsy for preimplantation genetic screening (PGS).

Preimplantation Genetic Diagnosis | Karyomapping Products

We offer a comprehensive karyomapping solution for preimplantation genetic diagnosis:

SureMDA Amplification System

For whole-genome amplification.

Infinium HumanKaryomap-12 DNA Analysis Kit

For microarray analysis.

NextSeq 550 System / iScan System

For scanning and imaging the HumanKaryomap BeadChip.

BlueFuse Multi Software

With karyomapping module for analysis.

Preimplantation Genetic Diagnosis | Translocation Products

24sure+ Microarray

Designed to improve the success of in vitro fertilization (IVF) by detecting subchromosomal imbalances in embryos of reciprocal translocation carriers.

Noninvasive Prenatal Testing Products and Services

verifi Prenatal Test

A noninvasive prenatal test service that screens for multiple fetal chromosomal aneuploidies using a single maternal blood draw. The verifi Prenatal Test screens for T21 (Down syndrome), T18 (Edwards syndrome), and T13 (Patau syndrome).

VeriSeq NIPT Analysis Software (16 Samples)

An easy-to-use, validated CE marked IVD NIPT analysis software that removes the burden of bioinformatics development.

Genetic Health Products

Targeted Panels

TruSight Cardio Sequencing Kit

A comprehensive, cost-effective solution for identifying causal variants implicated in inherited cardiac conditions (ICCs). It detects 174 genes related to 17 ICCs, including most cardiomyopathies and arrhythmias.

TruSight One Sequencing Panel

Targets 4800 genes, enabling labs to expand and streamline their sequencing portfolio.

TruSight Inherited Disease Panel

Focuses on researching severe, recessive pediatric onset diseases.

Cystic Fibrosis

MiSeqDx Cystic Fibrosis 139-Variant Assay

An FDA-cleared in vitro diagnostic (IVD) next-generation sequencing test designed to detect 139 CFTR variants.

MiSeqDx Cystic Fibrosis Clinical Sequencing Assay

The first FDA-cleared in vitro diagnostic (IVD) next-generation sequencing test designed to sequence all protein coding regions and intron/exon boundaries of the CFTR gene, including two large deletions, two deep intronic mutations, and indels in homopolymeric regions such as the 2184delA deletion.

Constitutional Cytogenetics

Infinium CytoSNP-850K BeadChip

Designed by international consortia to provide the most comprehensive coverage of cytogenetically relevant genes for cancer studies.

HumanCytoSNP-12 DNA Analysis BeadChip Kit

A 12-sample BeadChip array that enables analysis of genetic and structural variation in the human genome, such as duplications, deletions, amplifications, copy-neutral LOH, and mosaicism.

Sequencing Systems

MiSeq System

Desktop sequencer featuring a simple workflow, integrated data analysis software, and unmatched accuracy.

MiSeqDx Instrument

The first FDA-cleared platform for in vitro diagnostic (IVD) testing. It provides a research mode to generate accurate, reliable data.

NextSeq 500 System

Flexible desktop sequencer that supports multiple applications, from targeted profiling to whole-genome sequencing.

NextSeq 550 System

Sequencing and cytogenomic array scanning on a single system, with a seamless transition between applications.

The verifi Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.